Vaughan Nelson Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Vaughan Nelson Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,232,360	Closed	-$17.3M	–	234
2023 Q1	$17.3M	Sell	1,232,360 -22,450	-2%	-$322K	0.21%	112
2022 Q4	$18M	Sell	1,254,810 -9,140	-0.7%	-$144K	0.23%	120
2022 Q3	$32.3M	Buy	1,263,950 +276,930	+28%	+$6.95M	0.47%	71
2022 Q2	$28M	Buy	987,020 +369,335	+60%	+$11.7M	0.38%	82
2022 Q1	$21.8M	Buy	+617,685	New	+$20.7M	0.25%	108

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vaughan Nelson Investment Management's MRVI Position: Q2 2023 in Review

Vaughan Nelson Investment Management sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 1,232,360 shares — an estimated $17.3M sold.

Vaughan Nelson Investment Management first reported a position in MRVI in Q1 2022 and held it in 5 quarters. The position peaked at $32.3M in Q3 2022. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Vaughan Nelson Investment Management reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Vaughan Nelson Investment Management sold 1,232,360 Maravai LifeSciences shares in Q2 2023, an estimated $17.3M.
Vaughan Nelson Investment Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 5 quarters.
Vaughan Nelson Investment Management's Maravai LifeSciences position peaked at $32.3M in Q3 2022.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Vaughan Nelson Investment Management's 13F filing for Q2 2023, filed 3 Aug 2023.